Recruiting now—Ages 1 Year to 100 Years

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Sponsor: Novartis Pharmaceuticals · NCT05868629 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

What it tests

Non-investigationalother

Where it's running8 sites

Lundquist Inst BioMed at Harbor
Torrance, California 90509-2910
Recruiting now
- Steve Yoon(contact)+1 310 222 4107 [email protected]
- Andrew Gianoukakis(principal investigator)
Rocky Mountain Cancer Centers
Denver, Colorado 80218
Recruiting now
- Sierra Archuleta(contact)[email protected]
- Muath Dawod(principal investigator)
Johns Hopkins University
Washington D.C., District of Columbia 20016
Recruiting now
- Kai Hajos(contact)[email protected]
- Michael Pishvaian(principal investigator)
Duke Clinical Research Institute
Durham, North Carolina 27704
Recruiting now
- Kim Turnage Scoggins(contact)[email protected]
- Aman Opneja(principal investigator)
Oncology Hematology Care Inc
Cincinnati, Ohio 45242
Recruiting now
- Douglas Hart(contact)[email protected]
- Jayadev Mettu(principal investigator)
Sarah Cannon Research Institute
Nashville, Tennessee 37203
Recruiting now
- Brianah Ferby(contact)[email protected]
- Meredith Ann McKean(principal investigator)
El Paso Texas Oncology
El Paso, Texas 79902
Recruiting now
- Nicole Dean(contact)[email protected]
- Ines Sanchez-Rivera(principal investigator)
Texas Oncology San Antonio
San Antonio, Texas 78258
Recruiting now
- Norma Norris(contact)[email protected]
- Angel Mier-Hicks(principal investigator)

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Study participant with a BRAF V600E mutation-positive solid tumor as confirmed by a local laboratory test;
* At least 1 measurable lesion as defined by RECIST v1.1 per local review;
* Study participant previously not treated with dabrafenib and/or trametinib. Study participants who received dabrafenib and trametinib in the past for the treatment of other malignancies are eligible if treatment has been discontinued for greater than 1 year;
* Ability to provide scans for central imaging review

Exclusion Criteria:

* Those with the following tumor types: melanoma, NSCLC, ATC, BTC, glioma and CRC;
* Study participants who have contraindication to receive dabrafenib and/ or trametinib according to the local label;

Updated 2026-04-01 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.